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Purpose.T oi n v e s t i g a t et h ee ﬀects of nipradilol on retrobulbar hemodynamics. Methods. We investigated normal and normal-
tension glaucoma (NTG) eyes. Topical nipradilol (one eye) and placebo eye drops (fellow eye) were instilled for 1 week in
volunteers. Nipradilol was also instilled in NTG patients. Ultrasound color Doppler imaging for the posterior vessels was
performed before, 2hr, 1 week (for normal), and at 4 weeks (for NTG). Results. In normal eyes, there were signiﬁcant decreases in
the resistance index (RI) for the temporal short posterior ciliary arteries (PCA) at 2hr and for the ophthalmic arteries at 1 week.
There were no signiﬁcant changes in the placebo-treated eyes. In the NTG eyes, there was a signiﬁcant decrease in the RI for the
central retinal artery, nasal, and temporal PCA at 2hr and 4 weeks. Conclusion. Short-term observations found that nipradilol
increased the ocular blood ﬂow in normal and NTG eyes.
1.Introduction
Reduction of intraocular pressure (IOP) is one of the keys
to preventing glaucoma progression. In some normal-
tension glaucoma(NTG) patients, however, a visualﬁeldloss
progresses despite achieving a suﬃcient reduction of the IOP
[1]. Other factors that may be involved in this progression
include frequency of migraine, optic disc hemorrhages, and
low blood pressure. Many reports have proposed that there
is a relationship between NTG and circulatory disorders
or pathogenesis of the glaucomatous optic nerve change
[2–4].
To clarify the pathology in order to design new therapies,
it is necessary to obtain a better understanding of the phys-
iology of the circulatory dynamics in NTG eyes. As such,
several reports have brought up the importance of retrob-
ulbar hemodynamics in NTG. Short posterior ciliary arteries
separatefromtheposteriorciliaryarteriesandthenpenetrate
the eye wall around the insertion of the optic nerve head.
These are essential for supplying blood to the optic nerve
head [5]. In addition, these vessels also play an important
role in the ocular blood circulation. To evaluate this ocular
circulation, ultrasonic color Doppler imaging (CDI) is a very
useful tool [6].
Nipradilol(3,4-dehydro-8-(2-hydroxy-3-isopropylamino)
propoxy-3-nitroxy-2H-1-bezeopyran) is a newly developed
antiglaucoma ophthalmic agent, that is, a nonselective
β-blocker with selective α-blocking activities [7–9]. Topical
instillation of 0.25% nipradilol reduces the IOP and protects
the visual ﬁeld in patients with NTG, similar to that seen for
timolol [10, 11]. Nipradilol diﬀers from other antiglaucoma
eye drops in that it induces vasodilatory action. In addition,
nipradilol is able to rapidly reach the retrobulbar tissue at
pharmacologic eﬀective concentrations [12]. However, it is
still not clear as to how it is able to exert its antiglaucomatous
function within this region.
In the present study, we used the CDI system to examine
the eﬀect of topical 0.25% nipradilol administration on
blood ﬂow in various posterior ocular vessels in normal and
NTG eyes.2 Journal of Ophthalmology
2.SubjectsandMethods
2.1. Subject Demographics. All procedures were approved by
the Ethics Review Committee of the Mie University Hospital
and followed the tenets of the Declaration of Helsinki. All
subjects provided informed consent prior to initiation of the
study.
In the ﬁrst part of the study, to evaluate whether
nipradilol cause changes ocular blood ﬂow on normal eyes,
a total of 13 healthy volunteers with no ocular or systemic
medications (normal group) were evaluated. The aim of this
ﬁrst study is to see its tendency, so we scheduled during
one week to avoid side eﬀect on subjects. On the ﬁrst
experimental day, topical 0.25% nipradilol (Hypadil Kowa
Ophthalmic Solution, Kowa Inc., Tokyo, Japan) was instilled
in one eye, while a placebo that was identical to the vehicle
solution of the nipradilol eye drop and which was provided
with coded labels (kind gift from Kowa Inc., Tokyo, Japan)
was instilled in the fellow eye. Neither investigators nor
volunteers had any information as to which eye received the
nipradilol or placebo. Prior to instillation, both systemic and
eye examinations, which included CDI measurements, were
performed (baseline). The same examination was repeated
2hr after the ﬁrst instillation and at 1 week after the twice-
daily instillations.
As we evaluated the tendency of nipradilol on normal
eyes, we designed next study for NTG eyes. A total of 10
patients with bilateral NTG who had not received any ocular
medications for more than 4 weeks prior to evaluation
(NTG group) were examined in the second part of the
study. None of the patients had any history of intraocular
surgery nor were receiving any systemic medication. NTG
was deﬁned as progressive glaucomatous optic nerve damage
that occurred in the absence of either an increased IOP (less
than 21mmHg) or any other cause for optic nerve abnor-
malities. All systemic and ocular examinations, including the
CDI measurements, were performed before the nipradilol
instillation. Patients underwent the same examinations at
2hr after the initial instillation and after 4 weeks of twice-
daily instillations.
2.2. Systemic and Ocular Examination. Eye examinations,
which included IOP measurements, heart rate (HR), and
systemic blood pressure (BP), were measured for both the
normal and NTG groups using a BP-203RVII (Colin, Tokyo,
Japan).Ocularperfusionpressure(OPP)wascalculatedfrom
the collected data using the following formula:
OPP =
2
3
×

diastolic BP
+

1
3
×

systolic BP −diastolic BP

−IOP.
(1)
All CDI measurements were performed in the supine
position using an LOGIQ 500 system (GE Yokogawa Medical
Systems,Tokyo,Japan)equippedwitha7.5-MHzlineararray
transducer. Measurements were taken in the ophthalmic
artery (OA), central retinal artery (CRA), temporal short
posteriorciliaryartery(TPCA),andnasalshortposteriorcil-
iaryarteries(NPCAs).Usingtheseimages,wethencalculated
several parameters such as the peak systolic velocity (PSV),
end-diastolic velocity (EDV), and resistance index (RI) for
each vessel using the provided software. RI was calculated for
each vessel using the following formula:
RI =
(PSV −EDV)
PSV
. (2)
2.3. Statistical Analysis. All data are expressed as the mean ±
standarddeviation.Valuesofeachparameterbeforeandafter
administration were compared using the Wilcoxon signed-
rank sum test. An unpaired Student’s t-test was used for
comparison between the two groups. Values of P<0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Ocular Blood Flow after Nipradilol Administration in
Normal Eyes. There were no signiﬁcant diﬀerences between
the nipradilol and placebo-treated eyes for the IOP and OPP
baseline values. There were also no signiﬁcant diﬀerences
noted forthe HR, BP, and OPPbaseline valuesforthe 2-hour
and 1-week time points (Table 1). The mean IOP decreased
in both the nipradilol- and placebo-treated eyes at 2hr and
at 1 week as compared to the baseline values.
For the CDI examination, a large change in the retrob-
ulbar hemodynamics was noted after the nipradilol adminis-
tration (Table 2). PSV was signiﬁcantly decreased in the OA
at 2hr (P = 0.0044). There was a signiﬁcant increase in the
EDV (P = 0.0365) along with a signiﬁcant decrease of the RI
(P = 0.0164) in the TPCA. At 1 week, there was a signiﬁcant
decrease of the RI in the OA (P = 0.0329), and the EDV
increased signiﬁcantly in the CRA (P = 0.0409). In addition,
there was a tendency for the RI to decrease in the CRA and
for the EDV to increase in the OA and TPCA. Conversely,
there were no signiﬁcant changes for any of these CDI values
for the placebo-treated eye.
3.2.OcularBloodFlowafterNipradilolAdministrationinNTG
Eyes. As compared to the baseline values, there was a de-
crease in the mean IOP at 2hr (P = 0.0004) and at 4 weeks
(P = 0.0052) (Table 3). While there was also a signiﬁcant
decrease of the HR and OPP at 2hr (P<0.05) as compared
to baseline, no change was noted at 4 weeks (Table 3).
The CDI examination also found obvious changes in the
retrobulbar hemodynamics after nipradilol administration
in the NTG eyes compared to baseline. As seen in Table 4,
there were signiﬁcant decreases for the PSV in the OA (P =
0.0044), CRA (P = 0.0198), and TPCA (P = 0.0048) at
2hr. The EDV was also signiﬁcantly increased in the CRA
(P = 0.0003), NPCA (P = 0.0064), and TPCA (P = 0.0001),
and there was a signiﬁcant decrease in the RI in the CRA
(P = 0.0002), NPCA (P = 0.0023), and TPCA (P = 0.0007).
At 4 weeks, the only signiﬁcant increases were for the PSV
in the NPCA (P = 0.0365) and for the EDV in the CRAJournal of Ophthalmology 3
Table 1: Systemic and ocular parameters before and after topical application of nipradilol or placebo in controls.
Parameter
Nipradilol Placebo
Before 2hrs (P)1 w e e k ( P)B e f o r e 2 h r s ( P)1 w e e k ( P)
Intraocular pressure
(mmHg) 14.3 ±1.6 11.5 ±2.6
(0.0047)∗
11.2 ±2.2
(0.0071)∗ 13.7 ±1.3 12.5 ±2.5
(0.1212)
11.9 ±1.9
(0.0144)∗
Blood pressure
Systolic (mmHg) 125.7 ±10.2 126.2 ±7.1
(0.6542)
123.2 ±7.6
(0.7550) 125.7 ±10.2 126.2 ±7.1
(0.6542)
123.2 ±7.6
(0.7550)
Diastolic (mmHg) 73.1 ±6.6 73.2 ±6.4
(0.9591)
72.6 ±6.1
(0.8584) 73.1 ±6.6 73.2 ±6.4
(0.9591)
72.6 ±6.1
(0.8584)
Heart rate (beats/min) 69.8 ±9.7 67.2 ±8.6
(0.1967)
66.4 ±8.8
(0.1379) 69.8 ±9.7 67.2 ±8.6
(0.1967)
66.4 ±8.8
(0.1379)
Ocular perfusion pressure
(mmHg) 46.2 ±5.2 49.1 ±4.2
(0.0505)
48.5 ±3.9
(0.2477) 46.7 ±5.0 48.1 ±4.6
(0.3281)
47.7 ±3.9
(0.4496)
Wilcoxon signed-rank sum test.
Values are presented as mean ± standard deviation.
(P)
∗ < 0.05.
Table 2: Results of color Doppler imaging in normal volunteers.
Parameter
Nipradilo1 Placebo
Before 2hrs (P)1 w e e k ( P)B e f o r e 2 h r s ( P)1 w e e k ( P)
Ophthalmic artery
PSV (cm/sec) 35.8 ± 8.4 31.8 ± 8.6
(0.0044)∗
34.8 ± 8.6
(0.4769) 32.3 ± 10.8 31.8 ± 8.5
(0.6379)
31.6 ± 10.1
(0.5303)
EDV (cm/sec) 8.03 ± 2.40 7.52 ± 2.55
(0.4236)
8.76 ± 2.69
(0.0969) 8.17 ± 3.95 7.79 ± 2.13
(0.8753)
8.30 ± 2.89
(0.9063)
Resistance index 0.776 ± 0.035 0.764 ± 0.046
(0.2858)
0.749 ± 0.033
(0.0329∗) 0.753 ± 0.065 0.753 ± 0.037
(0.7836)
0.738 ± 0.036
(0.3078)
Central retinal artery
PSV (cm/sec) 11.3 ± 3.1 11.4 ± 2.4
(0.9999)
12.0 ± 2.5
(0.1095) 11.9 ± 2.4 12.4 ± 2.2
(0.3739)
12.6 ± 2.4
(0.1823)
EDV (cm/sec) 4.18 ± 1.06 4.28 ± 0.91
(0.5937)
4.67 ± 0.92
(0.0409∗) 4.53 ± 1.27 4.38 ± 1.03
(0.8240)
4.73 ± 0.94
(0.8589)
Resistance index 0.627 ± 0.038 0.622 ± 0.051
(0.4145)
0.606 ± 0.058
(0.1414) 0.623 ± 0.052 0.646 ± 0.059
(0.2662)
0.622 ± 0.057
(0.9999)
NPCA
PSV (cm/sec) 8.13 ± 1.85 8.36 ± 1.60
(0.4769)
8.02 ± 1.46
(0.8589) 9.43 ± 1.69 9.79 ± 1.22
(0.4243)
9.08 ± 0.89
(0.3743)
EDV (cm/sec) 3.43 ± 1.10 3.53 ± 0.78
(0.6833)
3.33 ± 0.85
(0.8588) 3.73 ± 0.81 4.06 ± 0.53
(0.2408)
3.66 ± 0.57
(0.5746)
Resistance index 0.584 ± 0.059 0.579 ± 0.041
(0.4496)
0.584 ± 0.067
(0.9999) 0.605 ± 0.051 0.582 ± 0.056
(0.2477)
0.596 ± 0.054
(0.3863)
TPCA
PSV (cm/sec) 10.2 ± 2.8 10.0 ± 3.1
(0.7895)
10.6 ± 2.9
(0.5337) 11.3 ± 3.0 11.0 ± 3.1
(0.7213)
10.9 ± 2.3
(0.2475)
EDV (cm/sec) 3.95 ± 1.27 4.25 ± 1.45
(0.0365)∗
4.36 ± 1.68
(0.4236) 4.53 ± 1.36 4.72 ± 1.74
(0.4496)
4.44 ± 1.35
(0.2662)
Resistance index 0.614 ± 0.060 0.578 ± 0.057
(0.0164)∗
0.600 ± 0.065
(0.2477) 0.597 ± 0.050 0.584 ± 0.043
(0.3739)
0.592 ± 0.074
(0.9292)
Values are presented as mean ± standard deviation. PSV: peak systolic velocity, EDV: end-diastolic velocity, NPCA: nasal short posterior ciliary artery, TPCA:
temporal short posterior ciliary artery.
Wilcoxon signed-rank sum test.
(P)
∗ < 0.05.4 Journal of Ophthalmology
Table 3: Systemic and ocular parameters before and after topical application of nipradilol in normal-tension glaucoma.
Parameter Before 2 hrs (P)4 w e e k s ( P)
Intraocular pressure (mmHg) 15.3 ± 2.2 13.7 ± 2.2 (0.0004)∗ 14.0 ± 1.3 (0.0052)∗
Blood pressure
Systolic (mmHg) 130.0 ± 19.2 131.0 ± 21.7 (0.6456) 129.0 ± 19.8 (0.7206)
Diastolic (mmHg) 78.7 ± 13.4 81.2 ± 11.8 (0.1363) 77.7 ± 11.6 (0.5139)
Heart rate (beats/min) 71.4 ± 11.9 65.7 ± 11.7 (0.0067)∗ 68.1 ± 13.6 (0.3316)
Ocular perfusion pressure (mmHg) 48.6 ± 9.2 51.5 ± 8.8 (0.0002)∗ 49.2 ± 8.8 (0.4443)
Wilcoxon signed-rank sum test.
Values are presented as mean ± standard deviation.
(P)
∗ < 0.05.
Table 4: Results of color Doppler imaging in normal tension glaucoma with topical nipradilol.
Parameter Before 2 hrs (P v a l u e ) 4w e e k( P value)
Ophthalmic artery
PSV (cm/sec) 28.4 ± 10.8 24.7 ± 9.3 (0.0028)∗ 26.0 ± 9.0 (0.0871)
EDV (cm/sec) 7.71 ± 3.73 7.07 ± 3.26 (0.0859) 7.44 ± 3.67 (0.3490)
Resistance index 0.725 ± 0.084 0.712 ± 0.071 (0.4552) 0.721 ± 0.058 (0.7022)
Central retinal artery
PSV (cm/sec) 9.89 ± 3.31 10.9 ± 4.4 (0.0198)∗ 10.3 ± 4.0 (0.3317)
EDV (cm/sec) 2.88 ± 1.17 3.50 ± 1.43 (0.0003)∗ 3.25 ± 1.35 (0.0133)∗
Resistance index 0.711 ± 0.046 0.676 ± 0.035 (0.0002)∗ 0.683 ± 0.041 (0.0010)∗
NPCA
PSV (cm/sec) 9.03 ± 3.23 9.52 ± 4.31 (0.3134) 7.67 ± 2.43 (0.0365)∗
EDV (cm/sec) 3.18 ± 1.40 3.77 ± 1.97 (0.0064)∗ 2.92 ± 0.94 (0.9108)
Resistance index 0.651 ± 0.061 0.607 ± 0.050 (0.0023)∗ 0.616 ± 0.052 (0.0124)∗
TPCA
PSV (cm/sec) 8.76 ± 2.53 10.2 ± 3.4 (0.0048)∗ 8.43 ± 2.24 (0.5256)
EDV (cm/sec) 2.95 ± 0.93 4.05 ± 1.43 (0.0001)∗ 3.25 ± 1.01 (0.1303)
Resistance index 0.662 ± 0.055 0.601 ± 0.048 (0.0007)∗ 0.615 ± 0.047 (0.0040)∗
Values are presented as mean ± standard deviation. PSV: peak systolic velocity, EDV: end-diastolic velocity, NPCA: nasal short posterior ciliary artery, TPCA:
temporal short posterior ciliary artery. Wilcoxon signed-rank sum test.
(P)
∗ < 0.05.
(P = 0.0133). A signiﬁcant decrease was noted for the RI
in the CRA (P = 0.0010), NPCA (P = 0.0124), and TPCA
(P = 0.0040).
4. Discussion
Using the CDI system, this study demonstrated the eﬀect of
topical nipradilol on retrobulbar hemodynamics in normal
and NTG eyes. Topical nipradilol markedly decreased the
peripheral vascular resistance in normal eyes as shown by the
EDV or RI in the TPCA at 2hr and in the OA at 1 week.
As we observed the tendency that nipradilol aﬀects normal
eyes, we also evaluated its eﬀects on NTG eyes. At both 2h
and 4 weeks in the NTG eyes, there was a decrease in the
peripheralvascularresistanceintheCRA,TPCA,andNPCA.
These results indicate that topical 0.25% nipradilol increases
the retrobulbar blood ﬂow in both normal and NTG eyes.
Recently, there have been many new instruments and
techniques developed for noninvasive measurements of
the ocular circulation, such as the laser Doppler method,
scanning laser Doppler ﬂowmetry, and the laser speckle
method [13], which can evaluate the circulation of the
visible vessels on the fundus. The CDI system used in
t h ep r e s e n ts t u d yc a nd e t e c tb l o o dﬂ o wb yo v e r l a y i n g
data on an ultrasonic B-mode image and then displaying
the real-time direction and velocity of the blood ﬂow of
the invisible retrobulbar vessels using the Doppler shift
frequency as the real-time blood ﬂow velocity. Further-
more, peripheral vascular resistance corresponds to the
resistance of the ciliary vascular bed in the optic disc
and is represented by the RI or EDV. This can be readily
calculated using the highest and lowest blood ﬂow velocities.
Since peripheral vascular resistance reﬂects the peripheral
arterial circulation, it is now widely used as an index of
therapeutic results [14]. Due to the high reproducibility
of the CDI system, it is particularly appropriate for blood
ﬂow measurements in the short posterior ciliary arteries
supplying blood to the cribriform plate [15]. The short
posterior ciliary arteries like NPCA and TPCA supply bloodJournal of Ophthalmology 5
to the anterior region of the cribriform plate directly or
through the peripapillary choroidal blood ﬂow, while the
CRA supplies blood to the disc surface and posterior region
of the cribriform plate. Thus, as compared to the OA and
CRA, the NPCA and TPCA are more closely associated with
the circulation in this region. During the development of
glaucomatous optic nerve damage, the cribriform plate of
the optic disc is the main region that is impaired [16].
Therefore, circulation disorders involving these vessels may
be related to the damages seen in NTG. In this study,
we demonstrated an improvement of circulation in the
TPCA/NPCA for the normal and NTG eyes after nipradilol
administration.
Nipradilol has been shown to generate nitric oxide
(NO) [17–20]. It is also well known that NO plays a
crucial role in the ocular circulation or visual transduction
[21]. When taken together, it is possible that nipradilol
induces NO production, which subsequently can lead to
an improvement in the retrobulbar hemodynamics. This
suggests that nipradilol might have an inﬂuence on the
anterior region of the cribriform plate and thus may be
able to prevent glaucomatous damage in the eye through its
donative production of NO.
Recently, many studies have examined the use of oral
medications to improve not only the general circulation but
also the local ocular circulation. For example, oral calcium
antagonists work not only as a hypotensive drug but also act
by improving the peripheral vascular resistance of the short
posterior ciliary arteries, thereby protecting the visual ﬁeld
[22]. While these ﬁndings demonstrate the importance of
changes in the circulation, the use of systemic medications
can sometimes lead to severe general side eﬀects. Conversely,
topical eye drops can reduce these side eﬀects and provide
much safer treatments. Eye drops generally penetrate the eye
via severalroutes, suchas the conjunctive,cornea, andsclera.
By being able to penetrate the eye from the periocular tissue,
nipradilol is able speciﬁcally to target the retina [23]. Our
ﬁndings for the retrobulbar arteries indicated that nipradilol
reached the posterior portion of the eye and not only had an
eﬀect on the retina via the sclera, but also was able to directly
alter the retrobulbar hemodynamics. This mechanism of
action makes it possible to improve the blood circulation
of the optic nerve and protect the eye from glaucomatous
damage.
While our ﬁndings are promising, the small patient
sample number and the short observation period did not
allow us to determine how long nipradilol is eﬀective or
whether it could prevent glaucomatous visual ﬁeld damage.
Further investigations on the improvement of retrobul-
bar hemodynamics after long-term use of topical 0.25%
nipradilol will need to be undertaken.
In summary, short-term observation indicated that top-
ical nipradilol increased ocular blood ﬂow by decreasing
resistance in the peripheral blood vessels of both normal
and NTG eyes. The use of topical drugs makes it possible
to inﬂuence retrobulbar hemodynamics through local pen-
etration and aﬀect the short posterior ciliary arteries. These
ﬁndings suggest that the use of topical 0.25% nipradilol may
be advantageous as compared to other antiglaucoma eye
drops.
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